风险评分模型的比较,以预测直接口服抗凝剂患者的胃肠道出血

Ilsoo Kim1, Joon Sung Kim2, Dae Young Cheung3

  • 1Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

概括

当前用于预测直接口服抗凝剂 (DOAC) 用户胃肠道出血 (GIB) 的风险评分,当患者同时接受抗血小板治疗时,其准确性较低. 未来的模型需要纳入抗血小板使用,以改善GIB预测.